bpc 157 leaky gut (Intestinal Permeability): What the Evidence Says BPC-157 & The Gut-Brain Axis:

How to balance enjoying life today with making choices that support long-term health and longevity [51:45]

Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA

While Alnylams Phase III APOLLO-B study hit both key primary and secondary endpoints, the FDA stated in the documents that the effects of patisiran compared to placebo on both endpoints were small, of questionable clinical meaningfulness, and may not be detectable by patients. Major discussion points during the adcomm meeting included whether these key endpoints were appropriate to ascertain clinical meaningfulness in the ATTR-CM population, and panelists expressed varying opinions on whether the magnitude of the benefit seen in trial data was clinically meaningful

Lab tests arent needed. Baseline CRP and metabolic panels catch rare inflammatory reactions